Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 30

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 30
---
 2025, certain shareholders of the Company, namely entities affiliated with BVF Partners L.P., Blue Owl
Healthcare Opportunities, and certain entities affiliated with OrbiMed (collectively with the directors and executive officers of the Company, the “Supporting Company Shareholders”), each entered into a support and voting
agreement with the Company (the “Voting and Support Agreements”). The Voting and Support Agreements set forth, among other things, the agreements of such Shareholders to vote their Common Shares, in favour of the approval of the
Arrangement Resolution, the Liquidation Resolution, the Liquidator Resolution and any proposal to adjourn or postpone the Special Meeting. The Supporting Company Shareholders own approximately 40% of the outstanding Common Shares that are eligible
to vote at the Special Meeting and, excluding certain directors and executive officers that are entitled to “collateral benefit” (as defined in MI 61-101), own approximately 41% of the outstanding
Common Shares that are eligible to vote in the majority-of-the-minority vote required under MI
61-101 as of the close of business on November 21, 2025.

Timing

Assuming that the Final Order is granted on or about January 23, 2026, and the other conditions precedent to completion of the Arrangement are
satisfied or waived to the extent legally permissible, the Parties expect to complete the Arrangement on or aboutJanuary30, 2026.

The Effective Date could be delayed or not occur at all for a number of reasons, including, but not limited to, an objection before the Court
at the hearing of the application for the Final Order or any delay or failure in satisfying the conditions to the completion of the Arrangement, including obtaining Shareholder approval at the Special Meeting.

Risk Factors

There are a number of risk
factors relating to the Arrangement, all of which should be carefully considered by the Shareholders. Risks relating to the Arrangement can be found in the section entitled “Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which is incorporated by reference herein.

Certain U.S. Federal Income Tax Considerations

Shareholders should read carefully the information in the section entitled “Certain U.S. Federal Income Tax Considerations of the Arrangement” of this Circular and Proxy Statement, which sets out a general summary of U.S. federal income tax considerations that may be relevant to U.S. Hold